Acquisition by Jacob Gary S of 30000 shares of Hepion Pharmaceuticals at 3.72 subject to Rule 16b-3
| HEPA Stock | USD 0.66 0.03 4.35% |
About 61% of Hepion Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Hepion Pharmaceuticals stock suggests that many investors are alarmed at this time. The current market sentiment, together with Hepion Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Hepion Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Hepion |
Filed transaction by Hepion Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Hepion Pharmaceuticals Fundamental Analysis
We analyze Hepion Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hepion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hepion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Hepion Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Hepion Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Hepion Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Hepion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hepion Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Hepion Pharmaceuticals Related Equities
| OCEA | Ocean Biomedical | 1.41 | ||||
| ELEV | Elevation Oncology | 1.64 | ||||
| ENVB | Enveric Biosciences | 2.94 | ||||
| ZURA | Zura Bio | 6.83 |
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |